Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia
Open Access
- 5 April 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 63 (1), 1-9
- https://doi.org/10.1093/cid/ciw209
Abstract
Background. Fluoroquinolones have equivalent oral and intravenous bioavailability, but hospitalized patients with community-acquired pneumonia (CAP) generally are treated intravenously. Our objectives were to compare outcomes of hospitalized CAP patients initially receiving intravenous vs oral respiratory fluoroquinolones. Methods. This was a retrospective cohort study utilizing data from 340 hospitals involving CAP patients admitted to a non–intensive care unit (ICU) setting from 2007 to 2010, who received intravenous or oral levofloxacin or moxifloxacin. The primary outcome was in-hospital mortality. Secondary outcomes included clinical deterioration (transfer to ICU, initiation of vasopressors, or invasive mechanical ventilation [IMV] initiated after the second hospital day), antibiotic escalation, length of stay (LOS), and cost. Results. Of 36 405 patients who met inclusion criteria, 34 200 (94%) initially received intravenous treatment and 2205 (6%) received oral treatment. Patients who received oral fluoroquinolones had lower unadjusted mortality (1.4% vs 2.5%; P = .002), and shorter mean LOS (5.0 vs 5.3; P < .001). Multivariable models using stabilized inverse propensity treatment weighting revealed lower rates of antibiotic escalation for oral vs intravenous therapy (odds ratio [OR], 0.84; 95% confidence interval [CI], .74–.96) but no differences in hospital mortality (OR, 0.82; 95% CI, .58–1.15), LOS (difference in days 0.03; 95% CI, −.09–.15), cost (difference in $−7.7; 95% CI, −197.4–182.0), late ICU admission (OR, 1.04; 95% CI, .80–1.36), late IMV (OR, 1.17; 95% CI, .87–1.56), or late vasopressor use (OR, 0.94; 95% CI, .68–1.30). Conclusions. Among hospitalized patients who received fluoroquinolones for CAP, there was no association between initial route of administration and outcomes. More patients may be treated orally without worsening outcomes.Keywords
Funding Information
- Agency for Healthcare Research and Quality (R01HS018723)
- National Heart, Lung
- National Institutes of Health (K01HL114745)
This publication has 28 references indexed in Scilit:
- An Unsupported Preference for Intravenous AntibioticsPLoS Medicine, 2015
- Guidelines for the management of adult lower respiratory tract infections - Full versionClinical Microbiology & Infection, 2011
- Fluoroquinolones in Community-Acquired PneumoniaDrugs, 2011
- Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP)Journal of Medical Economics, 2010
- Implementation of guidelines for sequential therapy with fluoroquinolones in a Belgian hospitalPharmacy World & Science, 2010
- Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based studyCurrent Medical Research and Opinion, 2009
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumoniaEuropean Respiratory Journal, 2004
- Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysisAmerican Journal Of Medicine, 2004
- The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumoniaJournal of Antimicrobial Chemotherapy, 1991